Cargando…

Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry

Epidemiology and outcome of myeloma are mainly reported from large university centers and collaborative groups, and do not represent ‘real-world’ patients. The Swedish Myeloma Registry is a prospective population-based registry documenting characteristics, treatment and outcome in newly diagnosed my...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blimark, Cecilie Hveding, Turesson, Ingemar, Genell, Anna, Ahlberg, Lucia, Björkstrand, Bo, Carlson, Kristina, Forsberg, Karin, Juliusson, Gunnar, Linder, Olle, Mellqvist, Ulf-Henrik, Nahi, Hareth, Kristinsson, Sigurdur Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830385/ https://www.ncbi.nlm.nih.gov/pubmed/29217784 http://dx.doi.org/10.3324/haematol.2017.178103

Ejemplares similares

Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study
por: Wålinder, Göran, et al.
Publicado: (2022)

Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
por: Jakobsen Falk, Ingrid, et al.
Publicado: (2017)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden
por: Moore, Kari Lenita Falck, et al.
Publicado: (2022)

Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends
por: Vélez, Ramón, et al.
Publicado: (2016)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

Fractures and survival in multiple myeloma: results from a population-based study
por: Thorsteinsdottir, Sigrun, et al.
Publicado: (2020)

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
por: Swaminathan, Bhairavi, et al.
Publicado: (2015)

History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study
por: Lindqvist, Ebba K., et al.
Publicado: (2016)

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
por: Ali, Mina, et al.
Publicado: (2018)

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients
por: Lemonakis, Konstantinos, et al.
Publicado: (2022)

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment
por: Susek, Katharina Helene, et al.
Publicado: (2020)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
por: Ramasamy, Karthik, et al.
Publicado: (2023)

Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden
por: Ali, Mina, et al.
Publicado: (2019)

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
por: Alzrigat, Mohammad, et al.
Publicado: (2016)

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
por: Nahi, Hareth, et al.
Publicado: (2019)

Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls
por: Rögnvaldsson, Sæmundur, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
por: Moreau, Philippe, et al.
Publicado: (2019)

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2016)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
por: Gran, Charlotte, et al.
Publicado: (2020)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

Potential value of pre-planned imaging of bone disease in multiple myeloma
por: Gundesen, Michael T., et al.
Publicado: (2023)

The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
por: Uttervall, Katarina, et al.
Publicado: (2014)

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
por: Went, Molly, et al.
Publicado: (2018)

Conditioning with melphalan 200 mg/m(2) and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care
por: Afram, Gabriel, et al.
Publicado: (2022)

Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
por: Duru, Adil Doganay, et al.
Publicado: (2015)

Epidemiology of multiple myeloma in Poland in the years 2008–2017
por: Waszczuk-Gajda, Anna, et al.
Publicado: (2020)

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
por: Westhrin, Marita, et al.
Publicado: (2018)

Germline variants at SOHLH2 influence multiple myeloma risk
por: Duran-Lozano, Laura, et al.
Publicado: (2021)

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
por: Went, Molly, et al.
Publicado: (2019)

Use of Linked Nordic Registries for Population Studies in Hematologic Cancers: The Case of Multiple Myeloma
por: Abildgaard, Niels, et al.
Publicado: (2023)

Dietary intake is associated with risk of multiple myeloma and its precursor disease
por: Thordardottir, Marianna, et al.
Publicado: (2018)

Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk
por: Duran-Lozano, Laura, et al.
Publicado: (2021)

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
por: Luo, Man (Melody), et al.
Publicado: (2020)

Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
por: Iida, Shinsuke, et al.
Publicado: (2021)

Recent progress in the treatment of multiple myeloma: updates and highlights from ASH 2008
por: Jagannath, Sundar
Publicado: (2009)

Does diagnostic delay of colorectal cancer result in malpractice claims? A retrospective analysis of the Swedish board of malpractice from 1995–2008
por: Hafström, Larsolof, et al.
Publicado: (2012)

Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
por: Nahi, Hareth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5erpscloqvr2ogfh4hb7l8ge4